시장보고서

상품코드

1553471

강직성 척추염 시장 규모, 점유율 및 동향 분석 보고서 : 약품 유형별, 유통 채널별, 지역별, 부문별 예측(2024-2030년)

Ankylosing Spondylitis Market Size, Share & Trends Analysis Report By Drug Class (Non-steroidal Anti Inflammatory, TNF Inhibitors), By Distribution Channel (Hospital Pharmacy), By Region, And Segment Forecasts, 2024 - 2030

발행일: 2024년 08월 | 리서치사:

Grand View Research | 페이지 정보: 영문 100 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

강직성 척추염 시장 성장 및 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계 강직성 척추염 시장 규모는 2024년부터 2030년까지 6.4%의 연평균 복합 성장률(CAGR)을 기록하여 2030년까지 91억 2,000만 달러에 달할 것으로 예상됩니다.

강력한 제품 파이프라인의 존재는 시장 성장을 가속화할 가능성이 높습니다. 예를 들어, UCB S.A.의 파이프라인 제품인 비멕시주맙은 임상 2b상 시험에서 좋은 결과를 얻었으며, 예측 기간 동안 시장에 출시될 가능성이 있는 의약품 후보물질입니다.

제약사들은 시장 점유율을 유지하기 위해 라벨 확대와 특허 연장을 목표로 하고 있으며, 2017년 10월 Johnson & Johnson Services는 활동성 건선성 관절염(PsA) 또는 활동성 강직성 척추염(AS) 치료제로서 AS 치료제인 심포니 아리아의 승인을 획득했습니다. 이러한 치료 영역의 발전은 시장 성장에 긍정적인 영향을 미칠 것으로 예상됩니다.

또한 유리한 상환 정책의 존재도 성장을 가속할 것으로 예상됩니다. 예를 들어, 캐나다(온타리오 주)의 공공 의약품 프로그램에서 Novartis AG는 강직성 경직증 치료제로 코센틱스의 상환을 발표했으며, Novartis AG가 발표한 논문에 따르면 약 20 - 40%의 환자가 항 TNF 약물로 충분한 임상적 개선을 얻지 못한다고 발표했습니다.

강직성 척추염 시장 보고서 하이라이트

TNF(종양괴사인자) 부문이 2023년 59.4%의 매출 점유율로 시장을 주도할 것으로 예상됩니다. 류마티스 관절염과 같은 자가면역질환을 관리하는 종양괴사인자를 표적으로 하는 TNF 억제제는 큰 성장이 예상됩니다.
비스테로이드성 항염증제(NSAID) 시장은 예측 기간 동안 CAGR 8.8%로 성장할 것으로 예상됩니다.
북미 강직성 척추염 시장은 2023년 57.9%의 가장 큰 매출 점유율을 차지했습니다.
주요 기업들은 시장 점유율을 확대하기 위해 제품 개발, M&A, 지역 확장 등의 전략을 채택하고 있습니다.
예를 들어, 2019년 1월 삼성바이오에피스(Samsung Bioepis Co., Ltd.)는 중국 내 제품 포트폴리오를 확대하기 위해 3SBio Inc.

세계의 강직성 척추염 시장 점유율, 지역별, 2023년·2030년, 백만 달러
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 중국
- 일본
- 인도
- 한국
- 호주
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 남아프리카공화국
- 쿠웨이트

제7장 경쟁 구도

최근 동향과 영향 분석 : 주요 시장 진출기업별
기업 분류
기업 히트맵 분석
기업 개요
- AbbiVie, Inc
- Amgen, Inc.
- Pfizer, Inc.
- UCB, Inc.
- Novartis AG
- Eli Lilly and Company
- Johnson and Johnson Services, Inc.
- Merck and Co., Inc.

LSH 24.10.10

Ankylosing Spondylitis Market Growth & Trends:

The global ankylosing spondylitis market size is expected to reach USD 9.12 billion by 2030, registering a CAGR of 6.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. Presence of a strong product pipeline is likely to accelerate market growth. For instance, the positive phase-2b results of UCB S.A. pipeline product, Bimekizumab, makes it a potential drug candidate to be launched in the market over the forecast period.

Pharmaceutical companies are aiming at label expansion and patent extension for maintaining their share in the market. In October 2017, Johnson & Johnson Services received approval for Simponi Aria for AS treatment for the treatment active psoriatic arthritis (PsA) or active ankylosing spondylitis (AS). Such advancements in therapy area are expected to have a positive effect on the market growth.

Furthermore, presence of favorable reimbursement policies is anticipated to propel the growth. For instance, in Canada (Ontario) under the province's public drug program, Novartis AG announced the reimbursement of Cosentyx for the treatment of ankylosing ankylosis. According to an article published by Novartis AG, approximately 20 to 40% of patients fail to achieve sufficient clinical improvement on anti-TNF drugs, which provides opportunities for companies to develop novel and effective drugs.

Ankylosing Spondylitis Market Report Highlights:

The TNF (Tumor Necrosis Factor) segment dominated the market and accounted for a revenue share of 59.4% in 2023. TNF inhibitors, which target tumor necrosis factors to manage autoimmune conditions such as rheumatoid arthritis, are anticipated to experience significant growth.
The Non-steroidal Anti-Inflammatory Drug (NSAID) market is expected to grow at a CAGR of 8.8% over the forecast years.
The North America ankylosing spondylitis market accounted for the largest revenue share of 57.9% in 2023
Key companies are adopting strategies, such as product development, M&A, and regional expansion, to increase their market share
For instance, in January 2019, Samsung Bioepis Co., Ltd. announced the strategic partnership with 3SBio Inc. to expand its product portfolio in China

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Global Ankylosing Spondylitis Market Variables, Trends, & Scope

3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
3.4. Global Ankylosing Spondylitis Market Analysis Tools
- 3.4.1. Porter's Analysis
  - 3.4.1.1. Bargaining power of the suppliers
  - 3.4.1.2. Bargaining power of the buyers
  - 3.4.1.3. Threats of substitution
  - 3.4.1.4. Threats from new entrants
  - 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
  - 3.4.2.1. Political landscape
  - 3.4.2.2. Economic and Social landscape
  - 3.4.2.3. Technological landscape
  - 3.4.2.4. Environmental landscape
  - 3.4.2.5. Legal landscape

Chapter 4. Global Ankylosing Spondylitis Market: Drug Class Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Global Ankylosing Spondylitis Market: Drug Class Movement Analysis, USD Million, 2023 & 2030
4.3. Non-Steroidal Anti Inflammatory Drugs (NSAIDs)
- 4.3.1. Non-Steroidal Anti-Inflammatory Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. TNF Inhibitors
- 4.4.1. TNF Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.4.2. Humira
  - 4.4.2.1. Humira Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.4.3. Simponi
  - 4.4.3.1. Simponi Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.4.4. Remicade
  - 4.4.4.1. Remicade Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.4.5. Enbrel
  - 4.4.5.1. Enbrel Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.4.6. Cimzia
  - 4.4.6.1. Cimzia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.4.7. Other TNF Inhibitors
  - 4.4.7.1. Other TNF Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Other Drug Classes
- 4.5.1. Other Drug Classes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Global Ankylosing Spondylitis Market: Distribution Channel Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Global Ankylosing Spondylitis Market: Distribution Channel Movement Analysis, USD Million, 2023 & 2030
5.3. Hospital Pharmacy
- 5.3.1. Hospital pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Retail Pharmacy
- 5.4.1. Retail pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Others
- 5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Global Ankylosing Spondylitis Market: Regional Estimates & Trend Analysis

6.1. Global Ankylosing Spondylitis Market Share, By Region, 2023 & 2030, USD Million
6.2. North America
- 6.2.1. North America Global Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.2.2. U.S.
  - 6.2.2.1. U.S. Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.2.3. Canada
  - 6.2.3.1. Canada Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.2.4. Mexico
  - 6.2.4.1. Mexico Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3. Europe
- 6.3.1. Europe Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.3.2. UK
  - 6.3.2.1. UK Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.3.3. Germany
  - 6.3.3.1. Germany Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.3.4. France
  - 6.3.4.1. France Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.3.5. Italy
  - 6.3.5.1. Italy Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.3.6. Spain
  - 6.3.6.1. Spain Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.3.7. Denmark
  - 6.3.7.1. Denmark Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.3.8. Sweden
  - 6.3.8.1. Sweden Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.3.9. Norway
  - 6.3.9.1. Norway Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Asia Pacific
- 6.4.1. Asia Pacific Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.2. China
  - 6.4.2.1. China Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.3. Japan
  - 6.4.3.1. Japan Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.4. India
  - 6.4.4.1. India Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.5. South Korea
  - 6.4.5.1. South Korea Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.6. Australia
  - 6.4.6.1. Australia Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.7. Thailand
  - 6.4.7.1. Thailand Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Latin America
- 6.5.1. Latin America Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5.2. Brazil
  - 6.5.2.1. Brazil Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5.3. Argentina
  - 6.5.3.1. Argentina Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Middle East and Africa
- 6.6.1. Middle East and Africa Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6.2. Saudi Arabia
  - 6.6.2.1. Saudi Arabia Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6.3. UAE
  - 6.6.3.1. UAE Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6.4. South Africa
  - 6.6.4.1. South Africa Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6.5. Kuwait
  - 6.6.5.1. Kuwait Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

7.1. Recent Developments & Impact Analysis by Key Market Participants
7.2. Company Categorization
7.3. Company Heat Map Analysis
7.4. Company Profiles
- 7.4.1. AbbiVie, Inc
  - 7.4.1.1. Participant's Overview
  - 7.4.1.2. Financial Performance
  - 7.4.1.3. Product Benchmarking
  - 7.4.1.4. Recent Developments/ Strategic Initiatives
- 7.4.2. Amgen, Inc.
  - 7.4.2.1. Participant's Overview
  - 7.4.2.2. Financial Performance
  - 7.4.2.3. Product Benchmarking
  - 7.4.2.4. Recent Developments/ Strategic Initiatives
- 7.4.3. Pfizer, Inc.
  - 7.4.3.1. Participant's Overview
  - 7.4.3.2. Financial Performance
  - 7.4.3.3. Product Benchmarking
  - 7.4.3.4. Recent Developments/ Strategic Initiatives
- 7.4.4. UCB, Inc.
  - 7.4.4.1. Participant's Overview
  - 7.4.4.2. Financial Performance
  - 7.4.4.3. Product Benchmarking
  - 7.4.4.4. Recent Developments/ Strategic Initiatives
- 7.4.5. Novartis AG
  - 7.4.5.1. Participant's Overview
  - 7.4.5.2. Financial Performance
  - 7.4.5.3. Product Benchmarking
  - 7.4.5.4. Recent Developments/ Strategic Initiatives
- 7.4.6. Eli Lilly and Company
  - 7.4.6.1. Participant's Overview
  - 7.4.6.2. Financial Performance
  - 7.4.6.3. Product Benchmarking
  - 7.4.6.4. Recent Developments/ Strategic Initiatives
- 7.4.7. Johnson and Johnson Services, Inc.
  - 7.4.7.1. Participant's Overview
  - 7.4.7.2. Financial Performance
  - 7.4.7.3. Product Benchmarking
  - 7.4.7.4. Recent Developments/ Strategic Initiatives
- 7.4.8. Merck and Co., Inc.
  - 7.4.8.1. Participant's Overview
  - 7.4.8.2. Financial Performance
  - 7.4.8.3. Product Benchmarking
  - 7.4.8.4. Recent Developments/ Strategic Initiatives

강직성 척추염 시장 규모, 점유율 및 동향 분석 보고서 : 약품 유형별, 유통 채널별, 지역별, 부문별 예측(2024-2030년)

Ankylosing Spondylitis Market Size, Share & Trends Analysis Report By Drug Class (Non-steroidal Anti Inflammatory, TNF Inhibitors), By Distribution Channel (Hospital Pharmacy), By Region, And Segment Forecasts, 2024 - 2030

강직성 척추염 시장 성장 및 동향 :

강직성 척추염 시장 보고서 하이라이트

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 세계의 강직성 척추염 시장 변수, 동향, 범위

제4장 세계의 강직성 척추염 시장 : 약제 클래스 추정·동향 분석

제5장 세계의 강직성 척추염 시장 : 유통 채널 추정·동향 분석

제6장 세계의 강직성 척추염 시장 : 지역 추정·동향 분석